Brokers Set Expectations for Zai Lab FY2025 Earnings

Zai Lab Limited (NASDAQ:ZLAB) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Zai Lab in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($1.38) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

Separately, Bank of America reiterated a “neutral” rating and issued a $36.10 target price (up from $29.00) on shares of Zai Lab in a report on Monday.

Zai Lab Stock Performance

Shares of NASDAQ ZLAB opened at $35.39 on Thursday. The stock has a 50 day moving average price of $28.10 and a 200 day moving average price of $26.25. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of -12.78 and a beta of 1.02. Zai Lab has a 52-week low of $13.48 and a 52-week high of $36.60.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The company had revenue of $109.07 million during the quarter, compared to analysts’ expectations of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%.

Institutional Trading of Zai Lab

Several hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in shares of Zai Lab during the 4th quarter worth approximately $29,000. Pictet Asset Management Holding SA acquired a new stake in Zai Lab in the fourth quarter valued at approximately $31,000. Barclays PLC grew its holdings in Zai Lab by 337.6% in the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after purchasing an additional 2,856 shares during the last quarter. US Bancorp DE increased its position in shares of Zai Lab by 1,671.9% during the fourth quarter. US Bancorp DE now owns 5,865 shares of the company’s stock worth $154,000 after purchasing an additional 5,534 shares in the last quarter. Finally, Jasper Ridge Partners L.P. purchased a new stake in shares of Zai Lab during the 4th quarter valued at $210,000. 41.65% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zai Lab

In other Zai Lab news, CEO Ying Du sold 50,000 shares of the stock in a transaction on Friday, February 28th. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the sale, the chief executive officer now owns 494,117 shares of the company’s stock, valued at approximately $17,032,212.99. This trade represents a 9.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Frazor Titus Edmondson III sold 14,544 shares of Zai Lab stock in a transaction on Friday, February 28th. The shares were sold at an average price of $32.98, for a total value of $479,661.12. Following the completion of the transaction, the insider now owns 14,328 shares in the company, valued at $472,537.44. This represents a 50.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 122,127 shares of company stock valued at $4,024,442. Company insiders own 13.88% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.